MedTrace Logo

Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)

NCT02310997 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2015-05-27

No results posted yet for this study

Summary

This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS).

The trial is for babies over 4 weeks old, children, and adults up to the age of 45.

Conditions

Interventions

OTHER

Umbilical Cord Blood Transplant

DRUG

Cyclophosphamide

RADIATION

Total body irradiation

DRUG

Busulfan

DRUG

Melphalan

DRUG

Fludarabine

Sponsors & Collaborators

Principal Investigators

  • Rachael Hough · University College London Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
28 Days
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02310997 on ClinicalTrials.gov